Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

PURPOSE: CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Ciprotti, Marika, Tebbutt, Niall C., Lee, Fook-Thean, Lee, Sze-Ting, Gan, Hui K., McKee, David C., O'Keefe, Graeme J., Gong, Sylvia J., Chong, Geoffrey, Hopkins, Wendie, Chappell, Bridget, Scott, Fiona E., Brechbiel, Martin W., Tse, Archie N., Jansen, Mendel, Matsumura, Manabu, Kotsuma, Masakatsu, Watanabe, Rira, Venhaus, Ralph, Beckman, Robert A., Greenberg, Jonathan, Scott, Andrew M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2015
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881374/
https://ncbi.nlm.nih.gov/pubmed/26124477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.4256
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller